Page 32 - 2021_07-Haematologica-web

N. Gagelmann and N. Kröger
7. Bacigalupo A. Hematopoietic stem cell transplants after reduced intensity condi- tioning regimen (RI-HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2000;25(8):803-805.
8. Kolb H-J, Schmid C. The FLAMSA concept- past and future. Ann Hematol. 2020;99(9): 1979-1988.
9. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J. Sequential regimen of chemotherapy, reduced-intensity condition- ing for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfu- sion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.
10. Bacigalupo A, Raiola AM, Lamparelli T, et al. Thiotepa-based reduced intensity condition- ing regimen: a 10 year follow up. Bone Marrow Transplant. 2007;40(11):1091-1093.
11. Langenhorst JB, van Kesteren C, van Maarseveen EM, et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Adv. 2019;3(14):2179- 2187.
12. Marks R, Potthoff K, Hahn J, et al. Reduced- toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particu- lar activity against advanced hematologic malignancies. Blood. 2008;112(2):415-425.
13. Martino R, Wreede L de, Fiocco M, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoi- etic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant. 2013;48(6):761-770.
14.Craddock C, Jackson A, Loke J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant out- comes in acute myeloid leukemia. J Clin Oncol. 2021;39(7):768-778.
15. Spyridonidis A, Labopin M, Savani BN, et al. Redefining and measuring transplant condi- tioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55(6):1114-1125.
16. Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus stan- dard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first com- plete remission: a prospective, open-label randomised phase 3 trial. Lancet. Oncol 2012;13(10):1035-1044.
17. Fasslrinner F, Schetelig J, Burchert A, et al. Long-term efficacy of reduced-intensity ver- sus myeloablative conditioning before allo- geneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective fol- low-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5(4):e161- e169.
18. Martino R, Badell I, Brunet S, et al. High- dose busulfan and melphalan before bone marrow transplantation for acute nonlym- phoblastic leukemia. Bone Marrow Transplant. 1995;16(2):209-212.
19. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell trans- plantation. Blood. 2001;97(3):631-637.
20.Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative
21.
regimen for allogeneic haemopoietic stem- cell transplantation in patients with acute myeloid leukaemia: an open-label, multicen- tre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525-1536.
Peccatori J, Mastaglio S, Giglio F, et al. Clofarabine and treosulfan as conditioning for matched related and unrelated hematopoietic stem cell transplantation: results from the Clo3o phase II trial. Biol Blood Marrow Transplant. 2020;26(2):316- 322.
31.Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-inten- sity conditioning and conventional high- dose conditioning for allogeneic hematopoi- etic stem cell transplantation using HLA- identical sibling donors in myelodysplastic syndromes. Blood. 2006;108(3):836-846.
32.Martino R, Henseler A, van Lint M, et al. Long-term follow-up of a retrospective com- parison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syn- dromes. Bone Marrow Transplant. 2017; 52(8):1107-1112.
33. Ringdén O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unre- lated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27):4570-4577.
34. Luger SM, Ringdén O, Zhang M-J, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47(4):203- 211.
35. Chhabra S, Ahn KW, Hu Z-H, et al. Myeloablative vs reduced-intensity condi- tioning allogeneic hematopoietic cell trans- plantation for chronic myeloid leukemia. Blood Adv. 2018;2(21):2922-2936.
36.McLornan D, Szydlo R, Koster L, et al. Myeloablative and reduced-intensity condi- tioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retro- spective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25(11): 2167-2171.
37.Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional mye- loablative conditioning allogeneic stem cell transplantation for patients with acute lym- phoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116 (22):4439-4443.
38. Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotrans- plants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256-4262.
39. Genadieva-Stavrik S, Boumendil A, Dreger P, et al. Myeloablative versus reduced inten- sity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016;27 (12):2251-2257.
40. Hayden PJ, Iacobelli S, Pérez-Simón JA, et al. Conditioning-based outcomes after allo- geneic transplantation for myeloma follow- ing a prior autologous transplant (1991- 2012) on behalf of EBMT CMWP. Eur J Haematol. 2020;104(3):181-189.
41. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myelo- ma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109(8):3588-3594.
42.Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865-873.
43. Schuurhuis GJ, Heuser M, Freeman S, et al.
22. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Fludarabine and tre- osulfan: a novel modified myeloablative reg- imen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma. 2007;48(12):2352-2359.
23.Kröger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosul- fan, fludarabine and ATG as preparative reg- imen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006;37:339-344.
24.Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC- FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(1): e28-e39.
25. Kröger N, Iacobelli S, Franke G-N, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplan- tation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35(19):2157-2164.
26. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-Intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syn- dromes. J Clin Oncol. 2017;35(11):1154- 1161.
27. Blaise D, Tabrizi R, Boher J-M, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic periph- eral blood stem cell transplantation: prospective clinical and socioeconomic eval- uation. Cancer. 2013;119(3):602-611.
28.Rashidi A, Meybodi MA, Cao W, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation in myelodysplastic syndromes: systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26(6):e138-e141.
29. Ma S, Shi W, Li Z, et al. Reduced-intensity versus myeloablative conditioning regimens for younger adults with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. J Cancer. 2020;11(17):5223-5235.
30. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospec- tive survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19 (12):2304-2312.
1802
haematologica | 2021; 106(7)